{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:19:00Z","timestamp":1788441540295,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GSK","award":["200870"],"award-info":[{"award-number":["200870"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01724-z","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:57:19Z","timestamp":1788440239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and Insights from the Mepolizumab Pregnancy Exposure Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5177-1759","authenticated-orcid":false,"given":"Keele E.","family":"Wurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-0378","authenticated-orcid":false,"given":"Subramanya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5568-568X","authenticated-orcid":false,"given":"Megan","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4675-7722","authenticated-orcid":false,"given":"Christina D.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1724_CR1","unstructured":"Updated methodology to estimate overall and unintended pregnancy rates in the United States. 2023. Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/124395. Accessed Jan 2026."},{"issue":"1","key":"1724_CR2","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","volume":"205","author":"AA Mitchell","year":"2011","unstructured":"Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hern\u00e1ndez-D\u00edaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1-8. https:\/\/doi.org\/10.1016\/j.ajog.2011.02.029.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1724_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/aog.0000000000002579","volume":"131","author":"DM Haas","year":"2018","unstructured":"Haas DM, Marsh DJ, Dang DT, Parker CB, Wing DA, Simhan HN, et al. Prescription and other medication use in pregnancy. Obstet Gynecol. 2018;131(5):789\u201398. https:\/\/doi.org\/10.1097\/aog.0000000000002579.","journal-title":"Obstet Gynecol"},{"key":"1724_CR4","unstructured":"United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Centers for Biologic Evaluation and Research. Postapproval pregnancy safety studies. Guidance for Industry. 2026. Available at: https:\/\/www.fda.gov\/media\/124746\/download. Accessed May 2026."},{"key":"1724_CR5","unstructured":"European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy; need for post-authorisation data. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf. Accessed Feb 2025."},{"key":"1724_CR6","unstructured":"European Medicines Agency. NUCALA (mepolizumab) summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Accessed Feb 2025."},{"key":"1724_CR7","unstructured":"FDA. NUCALA prescribing information. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed Aug 2025."},{"key":"1724_CR8","unstructured":"The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy (200870 NPSS (Nucala Pregnancy Surveillance Study)). Organization of Teratology Information Specialists (OTIS) Research Center; 2024."},{"key":"1724_CR9","unstructured":"GSK. The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy. Scientific result summary. Available at: https:\/\/www.gsk-studyregister.com\/trials\/200870. Accessed Nov 2025."},{"key":"1724_CR10","unstructured":"GSK. The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy. Protocol. Available at: https:\/\/www.gsk-studyregister.com\/trials\/200870. Accessed Nov 2025."},{"key":"1724_CR11","unstructured":"Centers for Disease Control and Prevention. 2016 Archived National Asthma Data. Available at: https:\/\/www.cdc.gov\/asthma\/archivedata\/2016\/2016-national-data.htm. Accessed Feb 2025."},{"key":"1724_CR12","unstructured":"Centers for Disease Control and Prevention. 2016 National Health Interview Survey (NHIS) Data. Available at: https:\/\/www.cdc.gov\/asthma\/nhis\/2016\/table4-1.htm. Accessed Feb 2025."},{"issue":"6","key":"1724_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2500\/aap.2015.36.3908","volume":"36","author":"DM Lang","year":"2015","unstructured":"Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36(6):418\u201324. https:\/\/doi.org\/10.2500\/aap.2015.36.3908.","journal-title":"Allergy Asthma Proc"},{"key":"1724_CR14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2147\/jaa.s327659","volume":"14","author":"L R\u00f6nnebjerg","year":"2021","unstructured":"R\u00f6nnebjerg L, Axelsson M, Kankaanranta H, Backman H, R\u00e5dinger M, Lundb\u00e4ck B, et al. Severe asthma in a general population study: prevalence and clinical characteristics. J Asthma Allergy. 2021;14:1105\u201315. https:\/\/doi.org\/10.2147\/jaa.s327659.","journal-title":"J Asthma Allergy"},{"key":"1724_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-9-24","volume":"9","author":"K Bahadori","year":"2009","unstructured":"Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. https:\/\/doi.org\/10.1186\/1471-2466-9-24.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"1724_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.anai.2021.07.010","volume":"127","author":"J Trevor","year":"2021","unstructured":"Trevor J, Lugogo N, Carr W, Moore WC, Soong W, Panettieri RA Jr, et al. Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2021;127(5):579-87.e1. https:\/\/doi.org\/10.1016\/j.anai.2021.07.010.","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol."},{"issue":"1","key":"1724_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-017-0409-3","volume":"17","author":"RY Suruki","year":"2017","unstructured":"Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74. https:\/\/doi.org\/10.1186\/s12890-017-0409-3.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"1724_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/bdra.20350","volume":"79","author":"A Correa","year":"2007","unstructured":"Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Reporting birth defects surveillance data 1968\u20132003. Birth Defects Res A. 2007;79(2):65\u2013186. https:\/\/doi.org\/10.1002\/bdra.20350.","journal-title":"Birth Defects Res A"},{"issue":"43","key":"1724_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.15585\/mmwr.mm6543a1","volume":"65","author":"C Ferr\u00e9","year":"2016","unstructured":"Ferr\u00e9 C, Callaghan W, Olson C, Sharma A, Barfield W. Effects of maternal age and age-specific preterm birth rates on overall preterm birth rates\u2014United States, 2007 and 2014. MMWR Morb Mortal Wkly Rep. 2016;65(43):1181\u20134. https:\/\/doi.org\/10.15585\/mmwr.mm6543a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"1724_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","volume":"135","author":"J Namazy","year":"2015","unstructured":"Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr., Chen H, Carrigan G, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407\u201312. https:\/\/doi.org\/10.1016\/j.jaci.2014.08.025.","journal-title":"J Allergy Clin Immunol"},{"key":"1724_CR21","unstructured":"GSK. The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy scientific result summary. Available at: https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/200870\/b5c02526-e85b-463c-af83-49eacd2e06b8\/8856c7cc-8ef0-4f52-82fc-ad372b930461\/gsk-200870-clinical-study-result-summary-v1.pdf. Accessed May 2025."},{"issue":"8","key":"1724_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/pds.3659","volume":"23","author":"S Sinclair","year":"2014","unstructured":"Sinclair S, Cunnington M, Messenheimer J, Weil J, Cragan J, Lowensohn R, et al. Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. Pharmacoepidemiol Drug Saf. 2014;23(8):779\u201386. https:\/\/doi.org\/10.1002\/pds.3659.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1724_CR23","unstructured":"ClinicalTrials.gov. Benralizumab Pregnancy Exposure Study. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03794999. Accessed Apr 2025."},{"key":"1724_CR24","unstructured":"AstraZeneca. The Benralizumab Pregnancy Exposure Study: a VAMPSS Post-Marketing Surveillance Study final study report. Available at: https:\/\/s3.amazonaws.com\/ctr-med-7111\/D3250R00026\/6ba559a5-7035-4629-90f4-a5ebcc42d2ed\/20731973-668c-439c-b5a8-023d8b23a80d\/OTIS_Benralizumab_Final_Analysis_Report_Synopsis_Redacted-v1.pdf. Accessed Apr 2025."},{"key":"1724_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001003","author":"AC Wu","year":"2021","unstructured":"Wu AC, McMahon PM, Welch E, McMahill-Walraven CN, Jamal-Allial A, Gallagher M, et al. Characteristics of new adult users of mepolizumab with asthma in the USA. BMJ Open Respir Res. 2021. https:\/\/doi.org\/10.1136\/bmjresp-2021-001003.","journal-title":"BMJ Open Respir Res"},{"issue":"12","key":"1724_CR26","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.clinthera.2021.10.010","volume":"43","author":"J Silver","year":"2021","unstructured":"Silver J, Molfino N, Bogart M, Packnett ER, McMorrow D, Wu J, et al. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. Clin Ther. 2021;43(12):2064\u201373. https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.010.","journal-title":"Clin Ther"},{"key":"1724_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/jaa.s189676","volume":"12","author":"JP Llanos","year":"2019","unstructured":"Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, et al. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43\u201358. https:\/\/doi.org\/10.2147\/jaa.s189676.","journal-title":"J Asthma Allergy"},{"issue":"19","key":"1724_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/bdr2.1954","volume":"113","author":"KM Sumner","year":"2021","unstructured":"Sumner KM, Ehlinger A, Georgiou ME, Wurst KE. Development and evaluation of standardized pregnancy identification and trimester distribution algorithms in U.S. IBM MarketScan\u00ae commercial and Medicaid data. Birth Defects Res. 2021;113(19):1357\u201367. https:\/\/doi.org\/10.1002\/bdr2.1954.","journal-title":"Birth Defects Res"},{"key":"1724_CR29","unstructured":"Georgiou ME, Mountcastle S, Ma L, Sumner KM, Wurst KE, editors. Nucala exposure in women of childbearing age and in pregnant women in US claims data, 2016\u20132019. In: 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 2021: Pharmacoepidemiol Drug Saf."},{"key":"1724_CR30","unstructured":"FDA. Sentinel initiative. Available at: https:\/\/www.fda.gov\/safety\/fdas-sentinel-initiative. Accessed Mar 2025."},{"key":"1724_CR31","unstructured":"Conception. The ConcePTION project: bridging the gap. Available at: https:\/\/www.imi-conception.eu\/. Accessed Feb 2025."},{"key":"1724_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.reprotox.2020.03.004","volume":"94","author":"Y Geissbuhler","year":"2020","unstructured":"Geissbuhler Y, Rezaallah B, Moore A. An alternative to product-specific pregnancy registries? PRIM; PRegnancy outcomes Intensive Monitoring. Reprod Toxicol. 2020;94:13\u201321. https:\/\/doi.org\/10.1016\/j.reprotox.2020.03.004.","journal-title":"Reprod Toxicol"},{"issue":"2","key":"1724_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22(2):127\u201340. https:\/\/doi.org\/10.1111\/j.1472-8206.2007.00552.x.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"1724_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-023-01291-7","volume":"46","author":"JL Richardson","year":"2023","unstructured":"Richardson JL, Moore A, Bromley RL, Stellfeld M, Geissb\u00fchler Y, Bluett-Duncan M, et al. Core data elements for pregnancy pharmacovigilance studies using primary source data collection methods: recommendations from the IMI ConcePTION project. Drug Saf. 2023;46(5):479\u201391. https:\/\/doi.org\/10.1007\/s40264-023-01291-7.","journal-title":"Drug Saf"},{"key":"1724_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418804760","volume":"11","author":"Y Geissb\u00fchler","year":"2018","unstructured":"Geissb\u00fchler Y, Vile J, Koren G, Guennec M, Butzkueven H, Tilson H, et al. Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure. Ther Adv Neurol Disord. 2018;11:1756286418804760. https:\/\/doi.org\/10.1177\/1756286418804760.","journal-title":"Ther Adv Neurol Disord"},{"key":"1724_CR36","doi-asserted-by":"publisher","first-page":"204209862412859","DOI":"10.1177\/20420986241285927","volume":"15","author":"TY Sree Sudha","year":"2024","unstructured":"Sree Sudha TY, Meena B, Pareek S, Singh H. Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions. Ther Adv Drug Saf. 2024;15:20420986241285930. https:\/\/doi.org\/10.1177\/20420986241285927.","journal-title":"Ther Adv Drug Saf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01724-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01724-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:57:21Z","timestamp":1788440241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01724-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":36,"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01724-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KEW and SK are employed by GSK and hold financial equities in GSK. MS was a co-investigator for the Mepolizumab Pregnancy Exposure Study, receives research support from Sanofi, and receives royalties from UpToDate. MD received payment as a graduate research assistant through an educational training agreement with GSK, at the time the manuscript was drafted. She is now employed as an epidemiologist contractor by GSK. CC has received research funding from the following industry sponsors and a foundation: Amgen; AstraZeneca; Bristol Myers Squibb; Celgene; Genzyme Sanofi-Aventis; Gilead; GSK; Hoffman La-Roche-Genentech; Janssen Pharmaceuticals; Leo Pharma, Sun Pharma Global FZE; Novartis; Pfizer, Inc.; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB Pharma, USA; and the Gerber Foundation.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided oral consent to be included in the original study.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to data interpretation. All authors reviewed and revised the manuscript critically for important intellectual content, agreed to submit to the current journal, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}